Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients fulfill the diagnostic criteria of functional dyspepsia as defined by Rome II criteria~* Age \> 18 years old~* Failure of treatment response to PPI, H2 receptor antagonist fo 8 weeks and domperidone for 4 weeks~Exclusion Criteria:~* Organic pathology detected by endoscopy~* GERD or IBS as dominant compliant~* Presence of any alarm symptom: anemia, recurrent vomiting, weight loss~* Concomitant Helicobacter pylori infection~* Concomitant use of neuroleptic or antidepressant, NSAID~* Previous gastrointestinal surgery~* Cardiac arrhythmia, untreated glaucoma or benign prostate hypertrophy~* Pregnancy~* Known hypersensitivity or contraindication for tricyclic antidepressant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imipramine (Type: ACTIVE_COMPARATOR): Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).